Metformin Special Concept Development (Uk)

Active Ingredient:: Metformin Hydrochloride
Origin:: EU

Metformin Special Concept Development (Uk) (Metformin Hydrochloride)

Q: What is Metformin Special Concept Development (Uk) used for?

Metformin Special Concept Development (Uk) contains metformin hydrochloride, a biguanide antidiabetic agent used primarily to improve blood‑glucose control in adults with type 2 diabetes mellitus. It works by decreasing hepatic glucose production and increasing the body’s sensitivity to insulin.

Q: How does metformin hydrochloride work in the body?

Metformin hydrochloride inhibits mitochondrial complex I, which reduces hepatic gluconeogenesis. It also activates AMP‑activated protein kinase (AMPK), leading to enhanced peripheral glucose uptake and improved insulin sensitivity, thereby lowering circulating glucose levels.

Q: What is the usual dose of metformin?

The dosage of metformin is individualized by the prescribing clinician based on the patient’s renal function, glycaemic targets, and tolerability. The prescriber determines the appropriate strength, frequency, and titration schedule for each patient.

Q: Is metformin safe during pregnancy or breastfeeding?

Metformin is classified as pregnancy category unknown; it should be used during pregnancy only when the potential benefit justifies any potential risk to the fetus. Limited data suggest it may be excreted in breast milk, so breastfeeding mothers should discuss risks and benefits with their healthcare provider.

Q: How do I order Metformin Special Concept Development from GNH India?

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Q: How does metformin compare with other antidiabetic drugs?

Metformin is often preferred as first‑line therapy for type 2 diabetes because it improves insulin sensitivity without causing weight gain and has a low risk of hypoglycaemia compared with sulfonylureas or insulin. Unlike newer agents such as GLP‑1 receptor agonists, it is administered orally and is generally less expensive.

Q: What are the recommended storage conditions for metformin?

Metformin tablets should be stored at ambient temperature, below 25 °C, in the original packaging to protect from moisture and light. Keep the product out of reach of children and avoid storing in humid or excessively hot environments.

Q: How is metformin administered?

Metformin is taken orally, usually with meals to reduce gastrointestinal discomfort. The tablets are swallowed whole with a glass of water; they should not be crushed, chewed, or dissolved unless a specific formulation permits it.

Q: What are the most serious risks associated with metformin?

The most serious risk is lactic acidosis, a rare but potentially fatal condition that can occur in patients with severe renal or hepatic impairment, hypoxia, or excessive alcohol intake. Prompt medical attention is required if symptoms such as rapid breathing, muscle pain, or abdominal discomfort develop.

Q: Who should not use metformin?

Metformin is contraindicated in patients with severe renal impairment (eGFR <30 mL/min/1.73 m²), acute or chronic metabolic acidosis, including diabetic ketoacidosis, and in those with known hypersensitivity to metformin or other biguanides.

Metformin Hydrochloride, the active ingredient in Metformin Special Concept Development (Uk), is a biguanide presented as an oral tablet for oral use. It lowers blood glucose levels and is used to manage type 2 diabetes mellitus in adult patients.

GNH India supplies Metformin Special Concept Development (Uk) as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Special Concept Development (Uk) Ltd

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Metformin Hydrochloride is a biguanide that improves glycaemic control in disorders of glucose metabolism.

Type 2 diabetes mellitus: reduces fasting and post‑prandial glucose by decreasing hepatic glucose output and increasing peripheral insulin sensitivity.
Prediabetes (impaired fasting glucose): helps delay progression to overt diabetes when combined with diet and exercise.
Polycystic ovary syndrome (off‑label): may improve insulin resistance and restore regular menstrual cycles.

How It Works

Metformin Hydrochloride primarily inhibits mitochondrial respiratory‑chain complex I, leading to reduced hepatic gluconeogenesis. It also activates AMP‑activated protein kinase (AMPK), which enhances peripheral glucose uptake and improves insulin sensitivity in muscle and adipose tissue, collectively lowering circulating blood glucose levels.

Side Effects

Metformin Hydrochloride may cause a range of adverse reactions.

Common Side Effects

Gastrointestinal upset: nausea, abdominal discomfort, and loss of appetite.
Diarrhoea: frequent loose stools, especially during treatment initiation.
Metallic taste: transient alteration in taste perception.
Vitamin B12 deficiency: reduced absorption with long‑term use.
Weight loss: modest reduction in body weight in some patients.

Serious or Rare Side Effects

Lactic acidosis: a rare but life‑threatening accumulation of lactate.
Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis.
Hepatic failure: marked liver dysfunction leading to metabolic disturbances.
Hypoglycaemia: uncommon when used alone but possible with concomitant insulin or sulfonylureas.
Pancreatitis: inflammation of the pancreas reported in isolated cases.

Precautions & Warnings

When prescribing Metformin Hydrochloride, clinicians should consider several safety measures.

Renal function: assess eGFR before initiation and monitor periodically; avoid use if eGFR <30 mL/min/1.73 m².
Lactic acidosis risk: contraindicated in patients with severe hepatic impairment, acute heart failure, or conditions predisposing to hypoxia.
Alcohol consumption: limit intake as it may increase the risk of lactic acidosis.
Vitamin B12 monitoring: consider periodic testing for deficiency during long‑term therapy.
Pregnancy and breastfeeding: use only if the potential benefit justifies the potential risk to the fetus or infant.
Store at ambient temperature: keep in the original container, protect from moisture and heat, and do not expose to temperatures above 25 °C.

Avoid Interactions

Metformin Hydrochloride can interact with several medicines, requiring careful management.

Major Interactions (Avoid)

Iodinated contrast agents: may precipitate acute renal failure and increase lactic acidosis risk.
Cimetidine: can raise plasma metformin concentrations, heightening toxicity.
Alcohol: synergistic effect on lactic acidosis development.

Moderate Interactions (Monitor Closely)

Beta‑blockers: may mask symptoms of hypoglycaemia.
Loop and thiazide diuretics: can affect renal clearance of metformin.
ACE inhibitors or ARBs: monitor renal function and electrolytes when combined.
Digoxin: may require dose adjustment due to altered renal handling.

Frequently Asked Questions

Metformin Special Concept Development (Uk) contains metformin hydrochloride, a biguanide antidiabetic agent used primarily to improve blood‑glucose control in adults with type 2 diabetes mellitus. It works by decreasing hepatic glucose production and increasing the body’s sensitivity to insulin.

Metformin hydrochloride inhibits mitochondrial complex I, which reduces hepatic gluconeogenesis. It also activates AMP‑activated protein kinase (AMPK), leading to enhanced peripheral glucose uptake and improved insulin sensitivity, thereby lowering circulating glucose levels.

The dosage of metformin is individualized by the prescribing clinician based on the patient’s renal function, glycaemic targets, and tolerability. The prescriber determines the appropriate strength, frequency, and titration schedule for each patient.

Metformin is classified as pregnancy category unknown; it should be used during pregnancy only when the potential benefit justifies any potential risk to the fetus. Limited data suggest it may be excreted in breast milk, so breastfeeding mothers should discuss risks and benefits with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Metformin is often preferred as first‑line therapy for type 2 diabetes because it improves insulin sensitivity without causing weight gain and has a low risk of hypoglycaemia compared with sulfonylureas or insulin. Unlike newer agents such as GLP‑1 receptor agonists, it is administered orally and is generally less expensive.

Metformin tablets should be stored at ambient temperature, below 25 °C, in the original packaging to protect from moisture and light. Keep the product out of reach of children and avoid storing in humid or excessively hot environments.

Metformin is taken orally, usually with meals to reduce gastrointestinal discomfort. The tablets are swallowed whole with a glass of water; they should not be crushed, chewed, or dissolved unless a specific formulation permits it.

The most serious risk is lactic acidosis, a rare but potentially fatal condition that can occur in patients with severe renal or hepatic impairment, hypoxia, or excessive alcohol intake. Prompt medical attention is required if symptoms such as rapid breathing, muscle pain, or abdominal discomfort develop.

Metformin is contraindicated in patients with severe renal impairment (eGFR <30 mL/min/1.73 m²), acute or chronic metabolic acidosis, including diabetic ketoacidosis, and in those with known hypersensitivity to metformin or other biguanides.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 05 Sep 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.